open access

Vol 86, No 5 (2018)
ORIGINAL PAPERS
Published online: 2018-10-30
Submitted: 2018-07-24
Accepted: 2018-10-15
Get Citation

QuantiFERON-TB-GOLD In-Tube in patients with sarcoidosis

Wojciech Jerzy Piotrowski, Adam J. Białas, Łukasz Gwadera, Anna Kumor-Kisielewska, Marek Fijałkowski, Zofia Kurmanowska, Jerzy Marczak, Witold Górski, Wojciech Angowski, Paweł Górski, Sylwia Kwiatkowska
DOI: 10.5603/ARM.2018.0037
·
Pubmed: 30378651
·
Adv Respir Med 2018;86(5):234-239.

open access

Vol 86, No 5 (2018)
ORIGINAL PAPERS
Published online: 2018-10-30
Submitted: 2018-07-24
Accepted: 2018-10-15

Abstract

Introduction: Sarcoidosis and tuberculosis (TB) are the diseases that share many similarities. Mycobacterium tuberculosis (MTB) culture results are the gold standard for the diagnosis of TB, but false positive results are not rare. The aim was to evaluate the utility of QFT in detecting latent TB infection in a group of sarcoidosis patients with negative history of TB and negative culture/BACTEC results, and checking sarcoidosis activity influence on the QFT results. Additionally, we assessed if QFT negative result may strengthen the suspicion that positive culture/BACTEC results are false positive. Material and methods: 37 culture-negative and 6 culture-positive sarcoidosis patients were enrolled. On the basis of clinical and radiological data TB was considered unlikely (false-positive results). A control group consisted of age-matched subjects with excluded TB (n = 37). QuantiFERON-TB GOLD In-Tube (QIAGEN, USA) was used according to the manual. Test validity was checked basing on the results obtained from a low-risk (n = 21) and active TB group (n = 23). Results: The frequency of positive results tended to be higher in MTB(–) sarcoidosis (24.3% vs. 13.5% for the control group, p = 0.37), but was similar to the general population. None of culture-positive sarcoidosis patients was QFT-positive. The positive results were equally distributed among patients with active and inactive sarcoidosis. Conclusions: QFT has been found to be the useful test for the detection of latent TB infection in sarcoidosis patients. In addition, we confirm that sarcoidosis activity does not negatively influence the result of QFT. Moreover, QFT would be proposed as a cost-saving diagnostic test providing additional diagnostic information when false positive MTB culture result in the sarcoidosis patient is highly suspected. However, in each case clinical, radiological and epidemiological data should be considered before taking the therapeutic decision.

Abstract

Introduction: Sarcoidosis and tuberculosis (TB) are the diseases that share many similarities. Mycobacterium tuberculosis (MTB) culture results are the gold standard for the diagnosis of TB, but false positive results are not rare. The aim was to evaluate the utility of QFT in detecting latent TB infection in a group of sarcoidosis patients with negative history of TB and negative culture/BACTEC results, and checking sarcoidosis activity influence on the QFT results. Additionally, we assessed if QFT negative result may strengthen the suspicion that positive culture/BACTEC results are false positive. Material and methods: 37 culture-negative and 6 culture-positive sarcoidosis patients were enrolled. On the basis of clinical and radiological data TB was considered unlikely (false-positive results). A control group consisted of age-matched subjects with excluded TB (n = 37). QuantiFERON-TB GOLD In-Tube (QIAGEN, USA) was used according to the manual. Test validity was checked basing on the results obtained from a low-risk (n = 21) and active TB group (n = 23). Results: The frequency of positive results tended to be higher in MTB(–) sarcoidosis (24.3% vs. 13.5% for the control group, p = 0.37), but was similar to the general population. None of culture-positive sarcoidosis patients was QFT-positive. The positive results were equally distributed among patients with active and inactive sarcoidosis. Conclusions: QFT has been found to be the useful test for the detection of latent TB infection in sarcoidosis patients. In addition, we confirm that sarcoidosis activity does not negatively influence the result of QFT. Moreover, QFT would be proposed as a cost-saving diagnostic test providing additional diagnostic information when false positive MTB culture result in the sarcoidosis patient is highly suspected. However, in each case clinical, radiological and epidemiological data should be considered before taking the therapeutic decision.

Get Citation

Keywords

IGRA, quantiferon test, sarcoidosis, tuberculosis

About this article
Title

QuantiFERON-TB-GOLD In-Tube in patients with sarcoidosis

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 5 (2018)

Pages

234-239

Published online

2018-10-30

DOI

10.5603/ARM.2018.0037

Pubmed

30378651

Bibliographic record

Adv Respir Med 2018;86(5):234-239.

Keywords

IGRA
quantiferon test
sarcoidosis
tuberculosis

Authors

Wojciech Jerzy Piotrowski
Adam J. Białas
Łukasz Gwadera
Anna Kumor-Kisielewska
Marek Fijałkowski
Zofia Kurmanowska
Jerzy Marczak
Witold Górski
Wojciech Angowski
Paweł Górski
Sylwia Kwiatkowska

References (31)
  1. Dubaniewicz A. Microbial and human heat shock proteins as 'danger signals' in sarcoidosis. Hum Immunol. 2013; 74(12): 1550–1558.
  2. Piotrowski WJ, Górski P, Duda-Szymańska J, et al. Mycobacterium tuberculosis as a sarcoid factor? A case report of family sarcoidosis. Am J Case Rep. 2014; 15: 216–220.
  3. Koth LL, Solberg OD, Peng JC, et al. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med. 2011; 184(10): 1153–1163.
  4. Maertzdorf J, Weiner J, Mollenkopf HJ, et al. TBornotTB Network. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A. 2012; 109(20): 7853–7858.
  5. Agrawal R, Kee AeRa, Ang L, et al. Tuberculosis or sarcoidosis: Opposite ends of the same disease spectrum? Tuberc Edinb Scotl. 2016; 98: 21–26.
  6. Lee MR, Chung KP, Chen WT, et al. Epidemiologic surveillance to detect false-positive Mycobacterium tuberculosis cultures. Diagn Microbiol Infect Dis. 2012; 73(4): 343–349.
  7. Smith-Rohrberg D, Sharma SK. Tuberculin skin test among pulmonary sarcoidosis patients with and without tuberculosis: its utility for the screening of the two conditions in tuberculosis-endemic regions. Sarcoidosis Vasc Diffuse Lung Dis. 2006; 23(2): 130–134.
  8. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011; 37(1): 88–99.
  9. Goletti D, Carrara S, Stefania C, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One. 2008; 3(10): e3417.
  10. Goletti D, Carrara S, Vincenti D, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect. 2006; 12(6): 544–550.
  11. Milman N, Søborg B, Svendsen CBo, et al. Quantiferon test for tuberculosis screening in sarcoidosis patients. Scand J Infect Dis. 2011; 43(9): 728–735.
  12. Gupta D, Kumar S, Aggarwal AN, et al. Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28(2): 95–101.
  13. Kempisty A, Białas-Chromiec B, Borkowska D, et al. Interferon gamma release assays based on M. tuberculosis-specific antigens in sarcoidosis patients. Pneumonol Alergol Pol. 2015; 83(2): 126–134.
  14. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160(2): 736–755.
  15. Kuś J, Demkow U, Lewandowska K, et al. [Prevalence of latent infection with Mycobacterium tuberculosis in Mazovia Region using interferon gamma release assay after stimulation with specific antigens ESAT-6 and CFP-10]. Pneumonol Alergol Pol. 2011; 79(6): 407–418.
  16. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992; 117(3): 177–183.
  17. Sester M, Sotgiu G, Lange C, et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011; 37(1): 100–111.
  18. Stephan C, Wolf T, Goetsch U, et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS. 2008; 22(18): 2471–2479.
  19. Kim EY, Park MS, Kim YS, et al. Risk factors for false-negative results of QuantiFERON-TB Gold In-Tube assay in non-HIV-infected patients with culture-confirmed tuberculosis. Diagn Microbiol Infect Dis. 2011; 70(3): 324–329.
  20. Altet-Gómez N, De Souza-Galvao M, Latorre I, et al. Diagnosing TB infection in children: analysis of discordances using in vitro tests and the tuberculin skin test. Eur Respir J. 2011; 37(5): 1166–1174.
  21. Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. Eur Respir J. 2010; 35(3): 619–626.
  22. Cho K, Cho E, Kwon S, et al. Factors Associated with Indeterminate and False Negative Results of QuantiFERON-TB Gold In-Tube Test in Active Tuberculosis. Tuberc Respir Dis (Seoul). 2012; 72(5): 416–425.
  23. Bhattacharya M, Dietrich S, Mosher L, et al. Cross-contamination of specimens with Mycobacterium tuberculosis: clinical significance, causes, and prevention. Am J Clin Pathol. 1998; 109(3): 324–330.
  24. Lai CC, Tan CK, Lin SH, et al. Molecular evidence of false-positive cultures for Mycobacterium tuberculosis in a Taiwanese hospital with a high incidence of TB. Chest. 2010; 137(5): 1065–1070.
  25. Krawczyk M, Brzostek A, Gorna A, et al. Epidemiological analysis of Mycobacterium tuberculosis strains isolated in Lodz, Poland. Int J Tuberc Lung Dis. 2011; 15(9): 1252–1258.
  26. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006; 203(2): 359–370.
  27. Idali F, Wahlström J, Müller-Suur C, et al. Analysis of regulatory T cell associated forkhead box P3 expression in the lungs of patients with sarcoidosis. Clin Exp Immunol. 2008; 152(1): 127–137.
  28. Chen X, Zhou B, Li M, et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol. 2007; 123(1): 50–59.
  29. Rozot V, Patrizia A, Vigano S, et al. Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis. Clin Infect Dis. 2015; 60(3): 432–437.
  30. Day CL, Abrahams DA, Lerumo L, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol. 2011; 187(5): 2222–2232.
  31. Barcellini L, Borroni E, Brown J, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J. 2016; 48(5): 1411–1419.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl